LCM
LTRN icon

Lynwood Capital Management’s Lantern Pharma LTRN Stock Holding History

Lynwood Capital Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,000
Closed -$73K – 135
2022
Q4 		$73K Buy
+12,000
New +$60.1K 0.09% 88
2022
Q1 		– Sell
-50,000
Closed -$399K – 145
2021
Q4 		$399K Buy
+50,000
New +$457K 0.38% 65

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Lynwood Capital Management's LTRN Position: Q1 2023 in Review

Lynwood Capital Management sold out of Lantern Pharma (LTRN) in Q1 2023, closing a stake of 12,000 shares — an estimated $73K sold.

Lynwood Capital Management first reported a position in LTRN in Q4 2021 and held it in 2 quarters. The position peaked at $399K in Q4 2021. 21 funds tracked by Wall St. Rank hold LTRN as of Q1 2023.

  • Lynwood Capital Management reported no remaining Lantern Pharma position as of Q1 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 12,000 Lantern Pharma shares in Q1 2023, an estimated $73K.
  • Lynwood Capital Management first reported a position in Lantern Pharma in Q4 2021 and held it in 2 quarters.
  • Lynwood Capital Management's Lantern Pharma position peaked at $399K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2023.

Based on Lynwood Capital Management's 13F filing for Q1 2023, filed 12 May 2023.